p.106 抽出テキスト

Recommendation Table 2 for electrocardiogram baseline assessment

An ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment. I C

In patients with an abnormal baseline ECG, referral to a cardiologist is recommended. I C

Recommendation Table 3 for cardiac biomarker assessment prior to potentially cardiotoxic therapies Baseline measurement of NP and/or cTn is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to be measured during treatment to detect CTRCD. I C Recommendation Table 4 for cardiac imaging modalities in patients with cancer General

Echocardiography is recommended as the first-line modality for the assessment of cardiac function in patients with cancer. I C

3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF. I B

GLS is recommended in all patients with cancer having echocardiography, if available. I C

Baseline cardiac imaging prior to potentially cardiotoxic therapies Baseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting anticancer therapy. I C Recommendation Table 5 for primary prevention of cancer therapy-related cardiovascular toxicity Management of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before, during, and after cancer therapy. I C Recommendation Table 6 for secondary prevention of cancer therapy-related cardiovascular toxicity

Management of CVD according to applicable ESC Guidelines is recommended before, during, and after cancer therapy. I C

Recommendation Table 7 for baseline risk assessment and monitoring during anthracycline chemotherapy and in the first 12 months after therapy TTE

Baseline echocardiography is recommended in all patients with cancer before anthracycline chemotherapy. I B

In all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment. I B

In high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing treatment. I C Cardiac serum biomarkers

Baseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy. I B

cTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is recommended in high- and very high-risk patients. I B Recommendation Table 8 for baseline risk assessment and monitoring during HER2-targeted therapies and in the first 12 months after therapy TTE

Baseline echocardiography is recommended before HER2-targeted therapies in all patients. I B

In patients receiving neoadjuvant or adjuvant HER2-targeted therapies, echocardiography is recommended every 3 months and within 12 months after completing treatment. I B In metastatic HER2+ disease, echocardiography is recommended every 3 months during the first year; if the patient remains asymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment. I C Cardiac biomarkers

Baseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies. I C

Continued Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026